The effects of heat shock (HS; 428 8 8 8 8C) on the cell cycle and underlying molecular mechanisms are astonishingly unexplored. Here, we show that HS caused rapid Cdc25A degradation and a reduction of cell cycle progression. Cdc25A degradation depended on Ser75 -Cdc25A phosphorylation caused by p38MAPK and Chk2, which phosphorylated Ser177 -Cdc25A that is specific for 14.3.3 binding. Upon HS, Cdc25A rapidly co-localized with 14.3.3 in the perinuclear space that was accompanied with a decrease of nuclear Cdc25A protein levels. Consistently, a 14.3.3 binding-deficient Cdc25A double mutant (Ser177/Ala-Tyr507/Ala) was not degraded in response to HS and there was no evidence for an increased co-localization of Cdc25A with 14.3.3 in the cytosol. Therefore, upon HS, p38, Chk2 and 14.3.3 were antagonists of Cdc25A stability. On the other hand, Cdc25A was protected by Hsp90 in HEK293 cells because the specific inhibition of Hsp90 with Geldanamycin caused Cdc25A degradation in HEK293 implicating that Cdc25A is an Hsp90 client. Specific inhibition of Hsp90 together with HS caused and accelerated degradation of Cdc25A and was highly cytotoxic. The results presented here show for the first time that Cdc25A is degraded by moderate heat shock and protected by Hsp90. We describe the mechanisms explaining HS-induced cell cycle retardation and provide a rationale for a targeted hyperthermia cancer therapy.
INTRODUCTION
Severe heat shock (HS; up to 44-458C) arrests the cell cycle either dependent or independent of p53 through upregulation of p21 and downregulation of cyclin D family members (1 -3) . Mild to moderate HS (40-438C) reflects the conditions of very high fever and is reached by hyperthermic cancer therapy (fever range whole body hyperthermia; FR-WBH) but the effects on the cell cycle and its regulators are rather unexplored. Mild HS was shown to upregulate cyclin D1 (4) implicating an induction of the lymphocyte cell cycle although this has so far not been investigated in detail. Furthermore, HS was shown to activate the stress protein p38MAPK (p38) (2, 4) . Activated p38 can phosphorylate Ser75 -Cdc25A (5 -7) and phosphorylation of Ser75 -Cdc25A destabilizes the protein (5, 8) . Toxic stress caused by various chemicals and clinical drugs (9, 10) , UV (11) and ionizing radiation (12, 13) leads to degradation of Cdc25A through the activation of checkpoint kinases (Chks) (14) , which makes this cell cycle regulator and oncogene a target for anticancer therapy. However, Cdc25A was never studied in response to HS. We found that moderate and short HS (428C; 20-60 min) destabilized Cdc25A and studied the causal mechanisms. In short, HS caused rapid phosphorylation of Cdc25A by p38 and Chk2, and its nuclear export to the perinuclear space where it accumulated in co-localization with 14.3.3, which was required for its degradation.
There is an ongoing debate on the assumption that the more often high fevers are experienced throughout a lifetime, the lower is the risk to develop certain types of cancer and also hyperthermia treatment of patients suffering from liver, kidney and bone cancer is successful, although locally applied temperatures are much higher than the temperatures described herein. Here, we provide a mechanistic rationale for these observations.
Since Cdc25A is over-expressed in a variety of malignancies such as breast-, pancreatic-, renal-, liver-, lung-, thyroid-, oesophageal-, endometrial-, colorectal cancers, malignant melanoma, glioma, and non-Hodgkin lymphomas (15) , the specific response of Cdc25A to HS could be exploited in adjuvant thermo therapy applied either strictly locally at the tumour site or systemically to also reach distant micro-metastases.
RESULTS

Moderate heat shock downregulates Cdc25A and inactivates Cdc2
It was shown that severe HS causes p532/p212-dependent as well as p53-independent cell cycle arrest (1, 3) suggesting that also different mechanisms are responsible for the inhibition of cell proliferation. Moderate HS was reported to even induce cyclin D1 in lymphocytes implicating a lymphocytic growth response as observed when fevering, i.e. upon infections (2, 4) . In HEK293 cells, cyclin D1 was also upregulated at 39-408C (mild HS; Fig. 1A and B). Induction of p21 was not observed at the tested temperatures (37 -438C; data not shown). When analysing the expression of Cdc25A protein in response to moderate HS, we found its rapid downregulation when HEK293 embryonic kidney cells (Fig. 1A-C) or HeLa endometrial carcinoma cells (Fig. 1E) were exposed to 428C. Thus, HS downregulated the Cdc25A oncogene in different cell types. As a consequence of Cdc25A depletion, the phosphorylation of Tyr15-Cdc2 (Cdk1) peaked (16) (Fig. 1C) because Tyr15-Cdc2 (Cdk1) is a substrate of activated Cdc25A phosphatase (15) , and this reduced cell cycle progression. In addition, also Cdc25B and Cdc25C levels dropped in HEK293 cells (Fig. 1D ) and HeLa cells (Fig. 1E ) upon 428C HS and this may have contributed to the accumulation of Tyr15-phosphorylation of Cdc2 as well. Conversely, in HEK 293 cells, 408C HS did not cause Tyr15-phosphorylation of Cdc2 and only in HeLa cells Cdc25B was strongly decreased after 408C HS. A significant number of HEK293 cells accumulated in the G1 phase upon HS (428C, 20 min) and subsequent cultivation for 24 and 48 h (Fig. 1F) . Heat shocking HEK293 cells for 60 and 90 min (428C) led to severe apoptosis after 72 h post-incubation time (Fig. 1I) , and until the onset of apoptosis cells remained growth retarded. The retardation of cell cycle progression upon 428C HS was demonstrated by reduced cell proliferation rate (Fig. 1G ) and significantly reduced incorporation of BrdU into the nascent DNA (Fig. 1H ).
Heat shock activates p38 and induces Ser75 -Cdc25A phosphorylation Searching for Cdc25A degrading signals upon HS, we studied the expression of checkpoint kinase 1 (Chk1), which when phosphorylated destabilizes Cdc25A. However, HS did not activate Chk1 and a specific Chk1 inhibitor (C 1 I) did not influence Ser75 -Cdc25A phosphorylation or stability ( Fig. 2A , left-side panels) and hence, Chk1 did not play a role upon HS-induced destabilization. This was in contrast to UV-or ionizing radiation (IR)-induced Cdc25A degradation, which is triggered by Chk1 (11, 12) , and for control reasons we show Chk1 activation upon exposure of HEK cells to 50 mJ UV irradiation ( Fig. 2A, right-side panels) . Also p38 can phosphorylate Ser75 -Cdc25A (5-7), and p38 is activated upon severe as well as mild HS (2, 4) . In the context of HS, this signal cascade (p38 to Ser75 -Cdc25A) has not been studied yet. HS induced the phosphorylation of Thr180/182 of p38 (indicative for its activation) and the phosphorylation of Ser75 -Cdc25A within 20 min was prevented by the specific p38 inhibitor SB203580 and also the destabilization of the Cdc25A protein level was blocked (Fig. 2B) .
Heat shock activates checkpoint kinase 2 and induces Ser177 -Cdc25A phosphorylation
In search of downstream degrading mechanisms, the phosphorylation of Ser177-Cdc25A, a site phosphorylated by Chk2 thereby forming a docking site for 14.3.3 (14,16) was analysed. The binding of 14.3.3 to phospho-Ser177 could be demonstrated, and the phosphorylation of Ser177 -Cdc25A is known to have a destabilizing effect (9, 14, 17) . HS slightly induced the phosphorylation of Thr68-Chk2 within 20 min. At this time point also a slight electrophoretic upshift became visible (also visible at the 60 min time-point) indicating an increase of additional (likely activating) phosphorylations at different site(s) (Fig. 3) . Specific inhibition of Chk2 activity by Chk2 inhibitor (C 2 I) caused an electrophoretic downshift equal to the migration of the control band and a reduction of the phospho-specific signal intensity. Upon HS also the phosphorylation of Ser177 -Cdc25A became induced within 20 and 60 min, which was reduced (but not reversed to control levels) in the presence of C 2 I. This indicated that Chk2 caused Ser177 -Cdc25A phosphorylation. The Cdc25A protein level was less reduced after 20 min compared with HS-mediated depletion of Cdc25A protein level shown in Figure 2 . There are several reasons for this unsteady response within 20 min of HS. First, the confluence of the cell culture plays a role (the higher the confluence at the time of the experiment, the higher the stability of Cdc25A). Secondly, even slight fluctuations of the incubator temperature (0.5 -1.08C) may cause a remarkable difference in such short time spans of HS (Fig. 1A) , and so does the transfer time from the maintenance incubator to the HS incubator. In pilot experiments using water bath-controlled HS, similar fluctuations were observed and therefore, we continued with incubatorcontrolled HS. However, we want to point out that HS induced the degradation of Cdc25A in every single experiment (at least after 60 min), which is the major finding we want to demonstrate. After 60 min of HS, Cdc25A protein expression was strongly reduced (Fig. 3) , whereas the phospho-specific antibody still detected considerable phopho-Ser177 levels. This implicated that low amounts of Cdc25A must have been highly phosphorylated. Specific inhibition of Chk2 by C 2 I, which also inhibited phosphorylation of Ser177 - To further study the involvement of phosphorylation as trigger mechanism of Cdc25A destabilization, it was tested whether HS-mediated Cdc25A degradation was dependent on 14.3.3. This protein was described as a mediator of nuclearcytoplasmic transport of Cdc25B and Cdc25C (14, 18, 19) , and as a tag for subsequent proteasomal degradation. A double-mutated (dmt) Cdc25A construct that cannot become phosphorylated at the Ser177Ala and Tyr506Ala mutated residues is 14.3.3 binding-deficient (16) . Upon HS, this dmtCdc25A construct exhibited increased stability in transfected HEK293 cells, whereas ectopic wild-type (wt) Cdc25A was degraded, such as endogenous Cdc25A (Fig. 4A , left-side panels show Cdc25A expression of those cells that were transfected with wtCdc25A, right-side panels the expression of dmtCdc25A-transfected cells). Ectopic myctagged Cdc25A constructs were detected by an anti-myc antibody and endogenous Cdc25A by a monoclonal antibody against Cdc25A (F6), which does not detect dmtCdc25A. The Cdc25A-specific bands are indicated by arrow heads. The transfection was carefully adjusted not to exceed 2 -3-fold overexpression (see Materials and Methods). The experiment analysing the stability of dmtCdc25A supported the hypothesis that Cdc25A stability upon HS was regulated through Chk2 activation and the phosphorylation of Ser177 -Cdc25A. Then, it was analysed which of the 14.3.3 isoforms co-precipitated Cdc25A. Co-transfection of wtCdc25A-V5 (fused to a 3 0 -V5 tag) with each of the 14.3.3 isoforms listed showed that 14.3.31 and 14.3.3u (t) were those isoforms which pulled down high amounts of Cdc25A (Fig. 4B ). For unknown reasons HA-antibody precipitated 14.3.3s inefficiently and therefore we continued the studies with 14.3.3u and myc-tagged Cdc25A.
Reciprocal pull-down assays confirmed that wtCdc25A co-precipitated HA-14.3.3u, whereas a binding-deficient HA-mt14.3.3 construct, which cannot associate with natural 14.3.3 binding partners, did not co-precipitate with Cdc25A (20) . Also dmtCdc25A was entirely 14.3.3 binding-deficient (Fig. 4C) . Next, we investigated where in the cell Cdc25A Figure 2 . HEK293 cells were exposed to 428C HS for 20 min and where indicated (A) Chk1 inhibitor SB218078 (C 1 I, 1 mM; as a phospho-Chk1 antibody control cells were exposed to 50 mJ UV and post-incubated for 30 min, right-side panels), or (B) specific p38 inhibitor SB203580 (SB, 1 mM) was included. Then, cells were lysed and subjected to western blot analysis using the indicated antibodies. HS induced Thr180/182-p38 phosphorylation (indicative for its activation) and in consequence phosphorylation of Ser75-Cdc25A within 20 min and the reduction in Cdc25A protein level. The correct position of the phospho Ser75-Cdc25A band was identified by overlaying this luminescence image with that of the Cdc25A blot, which was developed on the same membrane. Chk1, which also phosphorylates Ser75-Cdc25A, did not become activated upon HS. b-Actin was used as loading control. Figure 1 . (A) HEK293 cells were exposed to increasing temperatures (as indicated) for 60 min and the expression of Cdc25A and cyclin D1 was analysed by western blotting and (B) measured by densitometry that was calibrated to actin expression (numbers are in proportion to actin expression that was set as 1.0). (C, D) HEK293 and (E) HeLa cells were exposed to 428C heat shock (HS; left-side panels) for 20 and 60 min, or 408C for 60 min (right-side panels), lysed and prepared for western blot analysis using the indicated antibodies. After 60 min HS (428C), Cdc25A, B and C levels were decreased and phosphoTyr15-Cdc2 levels were increased. b-Actin was used as a loading control. (F) HEK293 cells were exposed to HS for 20 min and put back to 378C for the indicated times. Then cells were prepared for FACS analysis. A significant accumulation of HS-treated cells in G1 was observed after 24 and 48 h. HEK cells were exposed to 428C HS for 20 and 60 min and set back to 378C and (G) counted after 12 h, or (H) pulse-labelled subsequent to HS with BrdU for 2 h. Then, BrdU incorporation was measured using a FACSCalibur flow cytometer, and compared with untreated controls. (I) HEK293 cells were exposed to 428C HS for 60 and 90 min and put back to 378C for 48 and 72 h. Then, cells were stained with HO/PI, and analysed with fluorescence microscopy using a DAPI filter. Experiments were performed in triplicate, asterisks indicate significance and error bars SEM.
co-localized with 14.3.3 upon HS and for this, we used confocal microscopy. HEK293 cells were inappropriate for this type of experiment, because they detached from glass slides after HS (even when slides were coated with matrigel or fibronectin), thereby preventing a confocal in situ analysis, and therefore, HeLa cells were used for this investigation. Cells were serum-starved overnight to downregulate endogenous c-Myc and avoid interference with the myc-tag of the ectopic Cdc25A constructs. In untreated control cells, the majority of wtCdc25A and dmtCdc25A was located in the nucleus. Upon 20 min HS, the levels of nuclear wtCdc25A decreased but the co-localization of wtCdc25A with 14.3.3 increased in the perinuclear space ( Fig. 4D and E) . dmtCdc25A persisted in the nucleus and HS neither changed the protein level nor the extent of perinuclear co-localization with 14.3.3 ( Fig. 4D and E). Zeiss software allowed quantifying the extent of Cdc25A expression as well as 14.3.3 co-localization (Fig. 4D) . Since dmtCdc25A was completely 14.3.3 bindingdeficient (Fig. 4C) , the measured co-localization in untreated and HS-treated dmtCdc25A cells was non-specific (Fig. 4D) . Hence, we introduced a threshold (the green dashed line in Fig. 4D ) above which the Cdc25A-14.3.3 co-localization was considered specific. This demonstrated that Ser177-phosphorylation-dependent 14.3.3 binding played a role in the subcellular distribution and degradation of Cdc25A upon HS.
Cdc25A is an Hsp90 client in HEK293 cells
Since there exist antagonists of Cdc25A stability, one has to also postulate the existence of protagonists that counteract destabilization. We tested the idea that HS activated chaperones of the heat shock protein family. Hsp90 was shown to interact with its client Chk1 (21) , and cytarabine-activated Chk1, which was destabilized by the specific Hsp90 inhibitor 17-AAG, resulted in attenuated degradation of Cdc25A in HL60 cells (22) , and this evidenced a connection between Hsp90 and Cdc25A. Garcia-Morales et al. (23) demonstrated that Cdc25C and Cdc2 are Hsp90 clients. Further, Akt and Raf1 are Hsp90 clients (24 -26) and Galaktionov et al. (27) showed that Cdc25A co-immunoprecipitated with Raf and we provided evidence that also Akt was associated with Cdc25A and Raf (28) . It therefore seemed likely that also Cdc25A is in complex with Hsp90. Apparently, Hsp90 stabilizes various oncoproteins and/or their oncogenic activity (29) and thus, targeting Hsp90 is evaluated in clinical trials as anticancer therapeutic concept (30) (31) (32) . Geldanamycin (GD) specifically inhibits Hsp90 by competing with ATP for the ATP/ADP-binding pocket and thereby Hsp90 becomes inactivated in its chaperone function that is required for client stabilization. In case Cdc25A is an Hsp90 client, such as other proto-oncogenes, i.e. Raf1, Akt or c-jun (24, 26, 33) , GD was expected to destabilize Cdc25A. To confirm this, HEK293 and HeLa cells were treated with 1 mM GD for 1 and 24 h and the stability of Cdc25A and Akt (Hsp90 client) was analysed. As expected, Akt was degraded in both cell lines within 24 h, whereas Cdc25A became degraded only in HEK293 cells (Fig. 5A ). This implicated that specific co-chaperones required for Cdc25A -Hsp90 binding and activity (34) are limited in HeLa cells but not in HEK293 cells. Therefore, dependent on the cellular context, Cdc25A was an Hsp90 client. Treatment with GD caused an electrophoretic Cdc25A-upshift after 24 h (Fig. 5A ) and this phenomenon was accelerated in combination with HS (Fig. 5B) . Also Cdc25A depletion was accelerated upon GD and HS co-treatment (after 20), which further confirmed that Cdc25A was an Hsp90 client (Fig. 5B) . HS-mediated activation of p38 became additionally induced by GD co-treatment and this correlated with a substantial increase in Ser75 -Cdc25A phosphorylation, which faded after 60 min HS.
To formally analyse whether Cdc25A and Hsp90 appear in the same complex, Cdc25A-V5 was transiently overexpressed and immunoprecipitated with anti-Cdc25A antibody Figure 3 . HEK293 cells were exposed to 428C heat shock (HS) for 20 and 60 min and where indicated a specific Chk2 inhibitor (C 2 I, 10 mM) was included. Then cells were lysed and subjected to western blot analysis using the indicated antibodies. After 20 and 60 min HS Chk2 was phosphorylated at the activating Thr68 site. Furthermore, Cdc25A was phosphorylated at the Chk2-specific phospho Ser177 site (arrowhead) after 20 and 60 min and less phosphorylated after treatment with C 2 I. Chk2 protein level was unchanged. b-Actin was used as loading control. To better illustrate the HS-mediated phChk2 upshift, the panel at the right side gives a 2.5Â magnification of the control-and HS band (20 min). The correct position of the phospho Ser177-Cdc25A bands (or the phospho Thr68-Chk2 bands) was identified by overlaying this luminescence image with that of the Cdc25A blot (or the Chk2 blot, respectively), which was developed on the same membrane. Figure 4 . HEK293 cells were transfected with (A) wild-type (wt) Cdc25A-myc-tag cDNA (left-side panels) and double-mutated (dmt) Cdc25A-myc-tag cDNA (right-side panels) and then exposed to HS for the indicated times (min). Then cells were lysed and subjected to western blot analysis using the listed antibodies. Endogenous wt-and ectopic wtCdc25A-myc-tag was degraded after 20 min HS, whereas dmtCdc25A protein levels remained unchanged. The bars indicate the 72 kDa weight marker. b-Actin was used as loading control. (B) Co-immunoprecipitation of wtCdc25A-V5 with 14.3.3 isoforms: the indicated HA-tagged 14.3.3 cDNA isoforms and V5-tagged wtCdc25AcDNA were co-transfected into HEK293 cells and after 24-36 h cells were lysed and 14.3.3 was immunoprecipitated with HA antibody and co-precipitated Cdc25A was detected with V5 antibody. (C) Pull-down assay: HEK293 cells were transfected with the indicated cDNAs (wt14.3.3 u) and after 24-36 h cells were lysed by repeated freeze-thaw cycles under non-denaturing buffer conditions, and then Cdc25A was immunoprecipitated with monoclonal F6-or polyclonal M191 antibody. F6 was used to check the specificity of the Cdc25A/14.3.3 interaction. mt14.3.3 is a construct
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that cannot associate with natural 14.3.3 binding partners. The F6 antibody does not detect dmtCdc25A because it recognizes the C-terminus which is mutated in dmtCdc25A (not shown). Therefore, the analysis was performed with M191 antibody, which also detects dmtCdc25A. 14.3.3 Constructs carried a HA-tag and western blot analyses of co-immunoprecipitated 14.3.3 and lysate input was performed with HA antibody. (D) Serum-starved HeLa cells were grown on glass slides, transfected with wtCdc25A-myc-tag cDNA and dmtCdc25A-myc-tag cDNA subjected to HS for 20 min, fixed and prepared for doubleimmunofluorescence and examined under a confocal microscope. The green dashed line shows the threshold, below which co-localization is arbitrary, whereas above co-localization is specific. After 20 min HS, the co-localization of wtCdc25A/14. under non-denaturing conditions and the presence of Hsp90 in the precipitate was confirmed by western blotting (Fig. 5C , middle panel). The efficiency of the immunoprecipitates (IP) was controlled by anti-V5 immunoblot. Reciprocal IPwestern analysis (IP: Hsp90; WB: V5) confirmed the specificity of the Cdc25A -Hsp90 interaction (Fig. 5C , left-side panel). Also, after 428C HS (20 min) Hsp90 still co-precipitated with Cdc25A (Fig. 5C, right-side panel) . Throughout the time span investigated, we did not observe a change in the Hsp90 expression level (data not shown).
DISCUSSION
The dual-specificity phosphatase Cdc25A regulates the cell cycle and was shown to be sensitive to UV, IR, osmotic-, oxidative-and genotoxic stress (9 -12) . Here, we demonstrate for the first time that Cdc25A was rapidly downregulated upon HS at the high end of the physiological fever range (428C) (4, 35) , and reduced cell cycle progression causing an accumulation of cells in G1. Interestingly, also hyperthermic cancer therapy (FR-WBH) is performed around 41.58C. Upon 408C, HS Cdc25A expression was only moderately reduced. Unlike UV or IR, which cause Chk1-mediated phosphorylation and degradation of Cdc25A through tagging with the SCF b-TrCP ubiquitin -ligase complex at the phosphodegron around Ser81/87 -Cdc25A (13, 36, 37) , HS activated the kinases p38 and Chk2, but not Chk1. p38 phosphorylated Ser75 -Cdc25A (such as that described for Chk1) (8) and this may have as well facilitated the subsequent phosphorylation of Ser81/87 -Cdc25A and association with the SCF b-TrCP ubiquitin -ligase complex followed by degradation (13, 36) . Specific inhibition of p38-mediated Ser75 -Cdc25A phosphorylation abrogated destabilization of Cdc25A only in a small time-window and this evidenced that an additional degrading mechanism was activated as well. HS-mediated Figure 5 . (A) HEK293 and HeLa cells were exposed to the specific Hsp90 inhibitor geldanamycin (GD, 1 mM) for 1 and 24 h. After 24 h of treatment, Cdc25A was downregulated in HEK293 cells but not in HeLa cells. GD caused an electrophoretic upshift of Cdc25A in both cell lines after 24 h. (B) HEK293 cells were exposed to HS for 20 and 60 min and wherever indicated 1 mM GD was included. Then cells were lysed and subjected to western blot analysis using the indicated antibodies. b-Actin was used as loading control. HS and co-incubation with GD resulted in an increased phosphorylation of Ser75-Cdc25A and electrophoretic retardation and degradation of Cdc25A. Also the phosphorylation of Thr180/182-p38 was increased when cells were treated with HS and GD. b-Actin was used as loading control. (C) HEK293 cells were transfected with wtCdc25A-V5 cDNA and after 24-36 h cells were lysed by repeated freeze-thaw cycles under nondenaturing buffer conditions. Then, Hsp90 (left-side panels) was immunoprecipitated with anti-Hsp90 from Abcam and Cdc25A was detected using anti-V5 antibody. Reciprocally, Cdc25A (middle and right-side panels) was immunoprecipitated with M191 antibody and co-precipitated Hsp90 was detected by western blot analysis using anti-Hsp90 antibody from Cell Signaling. In the experiments that are depicted in the left and middle panels, cells were kept under normal culture conditions (CO), and in the experiment that is shown in the right-side panel cells were heat shocked (428C; HS) for 20 min. Precipitation efficiency was controlled by immunoblotting with anti-Hsp90 antibody from Cell Signaling (left side) or anti-V5 antibody (middle and right side).
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Chk2 activation led to the phosphorylation of Ser177 -Cdc25A (such as formerly described for Chk1) thereby, creating a 14.3.3 docking site (16) . It was shown that the binding of 14.3.3 to Cdc25 family proteins is mediated by phosphoserines within 14.3.3-binding consensus sequences of Cdc25 (38) . A second 14.3.3 docking site, Tyr506 -Cdc25A, was reported to become phosphorylated by Chk1 (14) . The prevention of 14.3.3 binding by Ser177Ala-Tyr506Ala mutations (16) inhibited the cytoplasmic sequestration of dmtCdc25A in HeLa cells and its degradation. Since the phosphorylation sites Ser75-, and Ser81/87 of Cdc25A were intact in the dmtCdc25A construct described herein and the degradation of Cdc25A was nevertheless blocked by a 14.3.3-binding mutant, a hypothetic SCF b-TrCP ubiquitin -ligase-dependent scenario was not the only cause for Cdc25A destabilization. Thus, HS-induced Cdc25A destabilization depended on binding to 14.3.3 and the relocation into the perinuclear space (see model suggested in Fig. 6 ). It has been shown that binding of 14.3.3 to the closely related family members, Cdc25B and Cdc25C, caused their sequestration to the cytoplasm (14, 18, 19) and finally their degradation. Cdc25A can largely compensate the deficiency in Cdc25B and Cdc25C (demonstrated with respective knockout mice), whereas Cdc25A (2/2) mice are embryonic lethal. Cdc25B and Cdc25C are therefore, not as relevant for survival as Cdc25A (15) . Most recently, Cdc25A was identified as a ratelimiting oncogene determining genomic stability and Cdc25A over-expression promotes tumours induced by the ErbB2-Ras pathway. Even a partial repression of Cdc25A is considered beneficial, as it reduces aggressive tumour development and improves prognosis in an MMTV-Ras/Cdc25A mouse model (15) . This justifies to search for therapeutic concepts targeting Cdc25A (39) .
The results support the interpretation that Hsp90 protected Cdc25A of HEK293 cells through a Hsp90 co-chaperone (Fig. 6) , such as the Hsp90 co-chaperone AHA1 maintained the activity of MEK1/2 and Erk1/2 (29). In our case however, the hypothetical co-chaperone was absent in HeLa cells. Currently, also the inhibition of Hsp90 is tested as anticancer target and the combination of GD with checkpoint inhibitors is considered as a promising approach. GD and HS (instead of checkpoint inhibitors) seems to be a concept with great potential, since HS treatment can be applied within the physiological range.
Here, a novel regulation of the Cdc25A oncogene was discovered providing a reasonable explanation for HS-induced cell cycle retardation and for the mechanisms destabilizing/ stabilizing Cdc25A upon HS and GD treatment and this can form a basis for a tailored Cdc25A-targeting hyperthermia cancer therapy.
MATERIALS AND METHODS
Chemicals
Specific inhibitors against p38 (SB203580; SB), HSP90 (Geldanamycin; GD), Chk1 (SB218078; C 1 I) and Chk2 (Chk2 inhibitor; C 2 I) were purchased from Calbiochem. Antibodies directed against ph(Tyr15)-Cdc2, ph(Thr180/182)-p38, p38, ph(Ser345)-Chk1, Chk1, ph(Thr68)-Chk2, Chk2 and Hsp90 were from Cell Signaling, against ph(Ser75)-Cdc25A, and Hsp90 from Abcam, against ph(Ser177)-Cdc25A from Abgent, against myc-tag from Invitrogen, against cyclin D1, p21, 14.3.3, Cdc25A (M191) and Cdc25A (F6) from Santa Cruz, against Cdc2 and b-actin from Sigma, V5 from Invitrogen, HA (high affinity, clone 3F10) was purchased from Roche, anti-mouse IgG was from Dako and anti-rabbit IgG from GE-Healthcare. Alexa-Fluor green 488-and Alexa-Fluor red 594-labelled antibodies were purchased from Molecular Probes, and Mowiol from Sigma.
Cell culture
HEK293 and HeLa cells were purchased from ATCC. Cells were grown in logarithmical growth phase at 378C in a humidified atmosphere containing 5% CO 2 in DMEM high glucose (HEK293) and low glucose (HeLa), both media were supplemented with 10% heat-inactivated fetal . This causes the phosphorylation of Cdc25A at S75 and S177. Hsp90 is still in complex (perhaps less stable) with Cdc25A. (3) 14.3.3 protein binds to phospho-S177 resulting in nuclear export. Since Cdc25A becomes degraded in the cytoplasm, we postulate that the protection by Hsp90 decreases throughout heat shock response (perhaps through loss of interaction), thereby allowing cell cycle retardation at the extreme end of the fever range.
calf serum, 1% L-Glutamine and 1% Penicillin/Streptomycin. All media and supplements were obtained from Life Technologies.
Transfection
HEK293 and HeLa cells were split into a 6-well plate and grown to 70% confluence before transfection in Penicillin/ Streptomycin-free medium. 7.5 ml of Lipofectamin 2000 (Invitrogen) and 1 mg of DNA (wtCdc25A-myc, dmtCdc25A-myc, wtCdc25A-V5 or the 14.3.3 isoforms) were mixed into 600 ml of OptiMEM transfection medium and incubated at room temperature for 20 min. In the meantime, cells were washed with phosphate-buffered saline and 1 ml of OptiMEM medium and the DNA and Lipofectamin 2000 mixture was added to the cells and incubated over night.
Cdc25A cDNA (without stop codon) was ligated in frame with a 3-terminal V5 tag into a pcDNA3.1-V5 vector (Invitrogen) and the frame was confirmed by DNA-sequencing. Double-mutated Cdc25A (dmtCdc25A -Ser177Ala and Tyr506Ala) was a generous gift of Dr Piwnica-Worms-this construct is also referred to as Ser178Ala and Tyr507Ala (when the starting N-terminal methionine is also counted).
Heat shock and inhibitor treatment
HEK293 and HeLa cells were grown to 90% confluence, then cells were pre-incubated with 1 mM of GD for 1 h, or 10 mM of C 2 I, 10 mM of SB, 1 mM C 1 I for 24 h and exposed to 428C HS for 20 and 60 min. After HS treatment cells were prepared for analyses as described thereafter.
Western blotting
After incubation with different inhibitors and exposure to 428C HS HEK293 cells were harvested, washed twice with ice-cold PBS (pH 7.2) and lysed in a buffer containing 150 mM NaCl, 50 mM Tris-buffered saline (Tris pH 8.0), 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride (PMSF) and protease inhibitor cocktail (PIC; from a 100Â stock). Then the lysate was centrifuged at 12 000 rpm for 20 min at 48C, and the supernatant was stored at 2208C until further analysis. Equal amounts of protein samples were separated by polyacrylamide gel electrophoresis (PAGE) and electroblotted onto PVDF membranes (Hybond, Amersham) overnight at 48C. Equal sample loading was controlled by staining membranes with Poinceau S. After washing with PBS/Tween-20 (PBS/T) pH 7.2 or Tris/Tween-20 (TBS/T) pH 7.6, membranes were blocked for 1 h in blocking solution (5% non-fat dry milk in PBS containing 0.5% Tween-20 or in TBS containing 0.1% Tween-20). Then, membranes were incubated with the first antibody (in blocking solution, dilution 1:500 to 1:1000) by gently rocking at 48C, overnight. Thereafter, the membranes were washed with PBS or TBS and further incubated with the second antibody (peroxidaseconjugated goat anti-rabbit IgG or anti-mouse IgG, dilution 1:2000 to 1:5000 in PBS/T or TBS/T) at room temperature for 1 h. Chemoluminescence was developed by the ECL detection kit (Amersham, UK) and then membranes were exposed to Amersham Hyperfilms.
Immunoprecipitation
Cells were harvested, washed with PBS and lysed in total lysis buffer (containing 20 mM HEPES, pH 7.9, 0.4 mM NaCl, 2.5% glycerol, 1 mM ethylenediamine tetraaceticacid, 1 mM PMSF, 0.5 mM NaF, 0.5 mM Na 3 VO 4 supplemented with 2 mg/ml aprotinin, 2 mg/ml leupeptin, 0.3 mg/ml benzamidin chloride and 10 mg/ml trypsin inhibitor) by repeated freezing and thawing. Supernatants were collected by centrifugation and protein concentrations were determined using the Bio-Rad protein assay. For immunoprecipitation, crude cell extracts (150 -300 mg) were precleared with 20 ml Protein GSepharose beads at 48C for 30-60 min. Afterwards, the indicated primary antibodies against Cdc25A (F6), Cdc25A (M191), HA or Hsp90 were added and incubated with constant rotation at 48C (overnight). After complex formation, immunoprecipitates were washed three times with buffer containing 50 mM Tris-HCl, pH 8.0, 1% NP-40, 150 mM NaCl, 10 mM b-glycerophosphate, 1 mM NaF, 0.1 mM Na 3 VO 4 , 0.2 mM PMSF supplemented with protease inhibitors. Immunoprecipitated proteins were then denatured and separated from the sepharose beads by adding SDS-sample buffer and boiling for 5 min (40, 41) .
Cell cycle distribution analysis
HEK293 cells were seeded in 6-wells and incubated at 378C for 24 h. At a confluence of 70%, cells were exposed to 428C for 20 min. After 12, 24 and 48 h, cells were harvested, washed with 5 ml cold PBS, centrifuged (600 rpm for 5 min) and re-suspended and fixed in 3 ml cold ethanol (70%) for 30 min at 48C. After two further washing steps with cold PBS, RNaseA and propidium iodide were added to a final concentration of 50 mg/ml each and incubated at 48C for 60 min before measurement. Cells were analysed on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) and cell cycle distribution was calculated with ModFit LT software (Verity Software House, Topsham, ME, USA).
Immunofluorescence
HeLa cells transiently transfected with wtCdc25A and dmtCdc25A were grown on chamber slides and exposed to 428C HS for 20 min. Then, cells were washed with PBS and fixed in 4% paraformaldehyde (10 min at room temperature), washed three times with PBS and permeabilized with 0.1% Triton X-100 in PBS at room temperature for 10 min. Then, cells were washed three times with PBS and incubated in 10% goat serum diluted with PBS pH 7.5 for 30 min to block unspecific binding of the antibodies. Thereafter, the cells were incubated with the primary antibody (dilution 1:50 in 2% BSA/PBS) in a humid chamber at room temperature for 45 min and then washed three times with PBS. Afterwards cells were incubated with fluorescence-labelled second antibody (dilution 1:1000 in PBS) in a humid chamber at room temperature for 45 min and then washed three times with PBS. Finally, cells were incubated with DAPI (dilution 1:50 000) at room temperature for 1 min and washed with PBS. The slides were covered with Mowiol and the analysis
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was performed using a Zeiss LSM5 Exicter confocal microscope using a 63Â objective.
BrdU incorporation
HEK293 cells were seeded in 6-wells, then exposed to 428C for 20 and 60 min and post-incubated with 10 mM of BrdU for 2 h. Cells were prepared following the instructions of the manufacturer (BrdU Flow Kit, Cat. No.: 552598, BD Pharmingen), except for the incubation with the fluorescent anti-BrdU antibody, which was incubated overnight at 48C (dilution of 1:50). Afterwards, the BrdU incorporation was measured and analysed by a FACSCalibur flow cytometer.
Determination of cell death-Hoechst 33258/propidium iodide double-staining
To measure apoptosis in MCF-7 clones, cells were seeded in 6-well plates, grown to 30% confluence, treated for increasing times with 428C HS, and were subsequently post-incubated at 378C for 48 and 72 h. Then, Hoechst 33258 and propidium iodide (final concentrations 5 mg/ml and 2 mg/ml, respectively) was directly added to the culture medium for 1 h, and stained cells were examined under a fluorescence microscope with a DAPI filter, photographed, analysed and counted. Experiments were performed in triplicate.
Statistics
Experiments were performed in triplicate and analysed using t-test (GraphPad Prism 4.0 program).
